Evidence map›Paper›PMID 28507793›Full record

ArticleOncoimmunology

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Hélène Roussel, Eléonore De Guillebon, Lucie Biard, Marion Mandavit, Laure Gibault, Elisabeth Fabre, Martine Antoine, Paul Hofman, Michèle Beau-Faller, Hélène Blons and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

Hélène RousselINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Eléonore De GuillebonINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Lucie BiardDepartment of Biostatistics and Medical Information, Hôpital Saint Louis, Paris, France.
Marion MandavitINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Laure GibaultDepartment of Pathology, Hôpital Européen Georges Pompidou, Paris, France.
Elisabeth FabreDepartment of Oncology, Hôpital Européen Georges Pompidou, Paris, France.
Martine AntoineDepartment of Pathology, Hôpital Tenon, Paris, France.
Paul HofmanDepartment of Pathology, Hôpital Pasteur, Nice, France.
Michèle Beau-FallerDepartment of Biochemistry and Molecular Biology, Hôpital de Hautepierre Strasbourg, Strasbourg, France.
Hélène BlonsDepartment of Biochemistry and Molecular BiologyINSERM UMR-S 1147, Hôpital Européen Georges Pompidou, Paris, France.
Claire DanelDepartment of Pathology Pompidou, Hôpital Bichat, Paris, France.
Françoise Le Pimpec BarthesDepartment of Thoracic Surgery, Hôpital Européen Georges Pompidou, Paris, France.
Alain GeyINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Clémence GranierINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Marie WislezGRC04 Théranoscan, Université P&M Curie, Paris, France.
Pierre Laurent-PuigDepartment of Biochemistry and Molecular BiologyINSERM UMR-S 1147, Hôpital Européen Georges Pompidou, Paris, France.
Stéphane OudardINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Patrick BrunevalDepartment of Pathology, Hôpital Européen Georges Pompidou, Paris, France.
Cécile BadoualINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Jacques CadranelGRC04 Théranoscan, Université P&M Curie, Paris, France.
Eric TartourINSERM U970, Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Hôpital Européen Georges-Pompidou · FRLa Ligue Contre le Cancer · FRAssistance Publique – Hôpitaux de Paris · FRHôpital Européen · FRHôpital Bichat-Claude-Bernard · FRHôpital d'Hautepierre · FRHôpital Pasteur · FRHôpital Saint-Louis · FRSorbonne Paris Cité · FRSorbonne Université · FRTHERANOSCAN : Biomarqueurs Théranostiques des Cancers Bronchiques Non à Petites Cellules

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplastic lymphoma kinase (ALK) inhibitors have been successfully developed for non-small cell lung carcinoma (NSCLC) displaying chromosomal rearrangements of the

Indexed as

ALK-positive adenocarcinomaimmunotherapyin situ quantitative cell imagingpredictive biomarkertumor microenvironment

Identifiers

PMID28507793
PMCPMC5414864
OpenAlexW2591374950

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.